Alterity Therapeutics Ltd (ATH)

Currency in AUD
0.012
+0.002(+20.00%)
Closed·
ATH Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
ATH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.0110.012
52 wk Range
0.0020.019
Key Statistics
Bid/Ask
0.011 / 0.012
Prev. Close
0.01
Open
0.011
Day's Range
0.011-0.012
52 wk Range
0.002-0.019
Volume
53.44M
Average Volume (3m)
17.77M
1-Year Change
175%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ATH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Alterity Therapeutics Ltd Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.

Compare ATH to Peers and Sector

Metrics to compare
ATH
Peers
Sector
Relationship
P/E Ratio
−9.0x−4.0x−0.7x
PEG Ratio
−0.17−0.050.00
Price/Book
2.6x4.0x2.6x
Price / LTM Sales
20.0x8.3x3.4x
Upside (Analyst Target)
-162.5%34.9%
Fair Value Upside
Unlock0.0%3.1%Unlock

Earnings

Latest Release
Aug 28, 2025
EPS / Forecast
-- / -0.0003
Revenue / Forecast
3.83M / 4.45M
EPS Revisions
Last 90 days

ATH Income Statement

People Also Watch

0.010
PER
+11.11%
4.700
RAC
+0.21%
2.890
MSB
-2.03%

FAQ

What Stock Exchange Does Alterity Therapeutics Trade On?

Alterity Therapeutics is listed and trades on the Sydney Stock Exchange stock exchange.

What Is the Stock Symbol for Alterity Therapeutics?

The stock symbol for Alterity Therapeutics is "ATH."

What Is the Alterity Therapeutics Market Cap?

As of today, Alterity Therapeutics market cap is 119.63M.

What Is Alterity Therapeutics's Earnings Per Share (TTM)?

The Alterity Therapeutics EPS (TTM) is -0.00.

When Is the Next Alterity Therapeutics Earnings Date?

Alterity Therapeutics will release its next earnings report on 02 Dec 2025.

From a Technical Analysis Perspective, Is ATH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Alterity Therapeutics Stock Split?

Alterity Therapeutics has split 0 times.

How Many Employees Does Alterity Therapeutics Have?

Alterity Therapeutics has 9 employees.

What is the current trading status of Alterity Therapeutics (ATH)?

As of 10 Oct 2025, Alterity Therapeutics (ATH) is trading at a price of 0.012, with a previous close of 0.01. The stock has fluctuated within a day range of 0.011 to 0.012, while its 52-week range spans from 0.002 to 0.019.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.